Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial

BACKGROUND: Lung nodules are a diagnostic challenge, with an estimated yearly incidence of 1.6 million in the United States. This study evaluated the accuracy of an integrated proteomic classifier in identifying benign nodules in patients with a pretest probability of cancer (pCA) ≤ 50%. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvestri, Gerard A., Tanner, Nichole T., Kearney, Paul, Vachani, Anil, Massion, Pierre P., Porter, Alexander, Springmeyer, Steven C., Fang, Kenneth C., Midthun, David, Mazzone, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians 2018
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689113/
https://www.ncbi.nlm.nih.gov/pubmed/29496499
http://dx.doi.org/10.1016/j.chest.2018.02.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689113/
https://www.ncbi.nlm.nih.gov/pubmed/29496499
http://dx.doi.org/10.1016/j.chest.2018.02.012

Ejemplares similares